Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

39.54 +1.30 (+3.40%)
Streaming Delayed Price Updated: 11:26 AM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Recap: Veracyte Q1 Earnings
Via Benzinga
Veracyte Announces First Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million. 
Via Benzinga
A Preview Of Veracyte's Earnings
Via Benzinga
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
From Veracyte, Inc.
Via Business Wire
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death Product Safety
Veracyte Announces Release of Inaugural ESG Report
From Veracyte, Inc.
Via Business Wire
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
From Veracyte, Inc.
Via Business Wire
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
From Veracyte, Inc.
Via Business Wire
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
From Veracyte, Inc.
Via Business Wire
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
From Veracyte, Inc.
Via Business Wire
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
From Veracyte, Inc.
Via Business Wire
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?
This diagnostics test maker has held up well over the last year. 
Via The Motley Fool
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
SMID Cap Life Science Update: Are You An Investor Or Trader?
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. 
Via Talk Markets
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
From Veracyte, Inc.
Via Business Wire
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.